Combination of HDAC inhibition and cytokine enhances therapeutic HPV vaccine therapy
Together, these findings provide a rationale for the combination of HPV vaccine, NHS-IL12, and Entinostat in the clinical setting for patients with HPV16-associated malignancies.
Authors
- Lisa K. Poppe (ORCID: https://orcid.org/0000-0002-9506-372X)
- Nicholas Roller
- Wiem Lassoued (ORCID: https://orcid.org/0009-0004-5742-6982)
- Asma S. Khelifa (ORCID: https://orcid.org/0000-0002-2608-0673)
- Miriam Marlene Medina-Enríquez (ORCID: https://orcid.org/0000-0001-9454-9114)
- Jeffrey Schlom (ORCID: https://orcid.org/0000-0001-7932-4072)
- James L. Gulley (ORCID: https://orcid.org/0000-0002-6569-2912)
- Caroline Jochéms (ORCID: https://orcid.org/0000-0002-9000-9855)
- Sofia R. Gameiro (ORCID: https://orcid.org/0000-0002-2392-8122)
- Katherine E Lothstein
- Masaya Miyamoto
- Daniel Burnett
Institutions
- National Institutes of Health (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-011074
- Citations
- 3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 2.39